We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Advion BioSystems Announces the Acquisition of NanoTek
News

Advion BioSystems Announces the Acquisition of NanoTek

Advion BioSystems Announces the Acquisition of NanoTek
News

Advion BioSystems Announces the Acquisition of NanoTek

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Advion BioSystems Announces the Acquisition of NanoTek"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Advion BioSciences, Inc. announces that its Advion BioSystems division has completed the acquisition of NanoTek, LLC. The addition of NanoTek to Advion’s micro and nano-scale LC-MS analytical platform enables the combined companies to assume a leadership position in micro-fluidic chemistry solutions.

Advion intends to provide a complete chemistry and analytics approach for imaging diagnostics, drug discovery and biomarker research. Prior to the acquisition, Advion had been the global distribution and support partner for NanoTek.

Joe Matteo, co-founder and CEO of NanoTek, will remain with Advion and serve as President of Advion’s Accelerated Chemistry Division, based in Knoxville,TN, and become a member of Advion’s Executive Committee. Advion plans to make significant investment in NanoTek R&D and chemistry development under Mr. Matteo’s leadership.

“This acquisition is extremely strategic for the company and accretive to earnings from day one. There are numerous synergies between the companies which became obvious to us as soon as we began the initial commercial partnership. We intend to rapidly accelerate the NanoTek global commercialization and extend the product lines into pre-existing demand areas” says David B. Patteson, CEO of Advion BioSciences, Inc.

“The acquisition is all about natural partnerships and very large opportunities” adds Joe Matteo. “We see the market potential in the same way, there are many ways to integrate our product lines and the customers embrace our combined vision. We could not have found a better partner, and this is a very strategic combination.”

Advertisement